Archived explainer. For the current picture see today's RCUS page.
ARCUS BIOSCIENCES IN (RCUS) is up +6.26% in the latest session. Our newswire has captured 5 stories on RCUS across 5 sources in the last 36 hours, with AI sentiment reading mixed (avg 55/100).
Arcus Biosciences shares rose 6.26% to $23.53 on Monday, driven by the release of new clinical data for its lead candidate casdatifan. The company reported promising results from its ARC-20 platform study in kidney cancer, which highlighted a 35-month median overall survival in late-line monotherapy. This data positioned the drug as a potential backbone therapy across multiple treatment lines for clear cell kidney cancer.
Arcus Biosciences presented new data from the ARC-20 platform study on October 20, 2026, via a Form 8-K filing. The results demonstrated a 35-month median overall survival in pooled late-line casdatifan monotherapy, signaling strong efficacy in heavily pretreated patients. The company is positioning casdatifan as a foundational treatment option across various stages of clear cell kidney cancer.
Several investment firms initiated or reaffirmed positive coverage following the data release. William Blair initiated coverage with an Outperform rating, while JP Morgan initiated coverage with an Overweight rating and a $41 price target. Wedbush reiterated its Outperform rating and maintained a $43 price target, and TD Cowen initiated coverage with a Buy rating. These analyst actions underscore the market's reaction to the clinical milestones.
The stock opened at $22.60, representing a 2.1% gap up from the prior close of $22.14. The session saw significant volatility, with a low of $18.00 at 8:35 AM ET and a high of $23.88 at 10:00 AM ET. Trading volume reached 1.7 million shares, which is 1.2 times the three-month daily average.
Fundamentals indicate a market capitalization of $2.8 billion. The company remains unprofitable with a trailing twelve-month EPS of -$3.86 and a net margin of -393.2%. Revenue declined 55.3% over the same period. The stock has a beta of 0.94 and trades within a 52-week range of $16.04 to $31.73. On October 20, the stock printed nine fresh 52-week highs and three fresh 52-week lows. Recent insider activity includes one sale totaling $85,000 by Chief Accounting Officer Alexander Azoy in August 2026.
Investors will monitor upcoming Phase 3 trial results for casdatifan, as current data remains pending final regulatory approval. The breadth of analyst coverage, including new initiations from major banks, suggests continued focus on the company's clinical progress and valuation potential.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Arcus Biosciences ( ($RCUS) ) has issued an announcement. On October 20, 2026, Arcus Biosciences reported new data from its ARC-20 platform study of casdatifan-base...
Why is Arcus Biosciences stock sliding today?
Arcus Biosciences presented new ARC-20 data positioning casdatifan (AB521) as a potential backbone therapy across clear cell kidney cancer treatment lines. Highlights included a 35-month median overall survival in pooled late-line monotherapy cohorts and first-line landmark PFS of 86% and 69% at 6 and 12 months, respectively, for casdatifan plus anti-PD-1. The company said its Phase 3 PEAK-20 study is on track to start by year-end, alongside the ongoing Phase 3 PEAK-1 program.
Filed: 2026-10-20 AccNo: 0001724521-26-000047 Size: 143 KB Item 8.01: Other Events
More on RCUS: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier RCUS move explainers: 2026-10-20 · 2026-09-11 · 2026-09-10